406 related articles for article (PubMed ID: 33039667)
1. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
Matsuno O; Minamoto S
Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
[TBL] [Abstract][Full Text] [Related]
2. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679
[TBL] [Abstract][Full Text] [Related]
3. Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study.
Santomasi C; Buonamico E; Dragonieri S; Iannuzzi L; Portacci A; Quaranta N; Carpagnano GE
Acta Biomed; 2023 Feb; 94(1):e2023028. PubMed ID: 36786266
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
Cavaliere C; Segatto M; Ciofalo A; Colizza A; Minni A; Messineo D; Lambiase A; Greco A; de Vincentiis M; Masieri S
Immunol Lett; 2022 Aug; 248():70-77. PubMed ID: 35752279
[TBL] [Abstract][Full Text] [Related]
5. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
Tversky J; Lane AP; Azar A
Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
[TBL] [Abstract][Full Text] [Related]
8. The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma.
De Corso E; D'Amato M; Carpagnano GE; Pelaia G; Bonini M
Curr Allergy Asthma Rep; 2023 May; 23(5):237-248. PubMed ID: 36995525
[TBL] [Abstract][Full Text] [Related]
9. Effect of Benralizumab in Patients With Severe Eosinophilic Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Case Series.
Chitguppi C; Patel P; Gandler A; Murphy K; Khoury Md T; Monostra P; Bork S; Toskala E; Rabinowitz M; Rosen M; Nyquist G; Most J
Am J Rhinol Allergy; 2021 Sep; 35(5):559-567. PubMed ID: 33302694
[TBL] [Abstract][Full Text] [Related]
10. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Taguchi A; Yamamoto H; Hasebe K; Shoji K
Respir Med Case Rep; 2020; 30():101135. PubMed ID: 32612919
[TBL] [Abstract][Full Text] [Related]
13. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study
D'Amato M; Menzella F; Altieri E; Bargagli E; Bracciale P; Brussino L; Caiaffa MF; Canonica GW; Caruso C; Centanni S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Ori A; Simoni L; Boarino S; Vitiello G; Aliani M; Del Giacco S
Front Allergy; 2022; 3():881218. PubMed ID: 35769575
[TBL] [Abstract][Full Text] [Related]
15. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
16. The Role of Fractional Exhaled Nitric Oxide in Diagnosing Asthmatic Type 2 Chronic Rhinosinusitis With Nasal Polyps.
Park JA; Cha H; Yang SK; Ryu HT; Kim DW; Hong SN; Yang MS; Kim DW
Am J Rhinol Allergy; 2023 Sep; 37(5):524-530. PubMed ID: 37160729
[TBL] [Abstract][Full Text] [Related]
17. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
18. Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment.
Mansur AH
Respir Med Case Rep; 2022; 35():101559. PubMed ID: 34976716
[TBL] [Abstract][Full Text] [Related]
19. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
20. [The study of association of chronic rhinosinusitis inflammation subtype with bronchial inflammation phenotype].
Zhang M; Wang JT; Wu DW; Tan LP
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Jan; 32(1):48-52. PubMed ID: 29798210
[No Abstract] [Full Text] [Related]
[Next] [New Search]
